On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department of Justice (DOJ) to resolve multi-year civil and criminal investigations into the companyﾒs past marketing practices related to its opioid medicines.

Purdue accepted responsibility for specified misconduct that took place before Jun. 2017 and resolved allegations regarding conduct between 2007 and February 2018 by pleading guilty and agreeing to pay fines and forfeiture. The overwhelming majority of these settlement funds were directed to state, local and tribal governments to address the opioid crisis.